Posted on 22/07/202422/07/2024 by sciencefather 73 / 100 Powered by Rank Math SEO Dr. Nitin Pal Kalia | Immunology and Microbiology | Best Researcher Award Dr. Nitin Pal Kalia, Assistant Professor, National Institute of Pharmaceutical Education and Research Hyderabad, India š Dr. Nitin Pal Kalia š, an esteemed Assistant Professor at the National Institute of Pharmaceutical Education and Research, Hyderabad, India, is renowned for his groundbreaking research in Immunology and Microbiology š§¬š¬. His innovative work has earned him the prestigious Best Researcher Award š, recognizing his significant contributions to the scientific community š. Dr. Kalia’s research focuses on understanding the immune system’s complexities and developing novel therapeutic strategies to combat infectious diseases šš¦ . His dedication to advancing pharmaceutical education and research has made him a prominent figure in his field šš. š©āš Profile Googlescholar, Orcid šĀ Education š Dr. Nitin Pal Kalia earned his Ph.D. in Biotechnology from the Indian Institute of Integrative Medicine, Jammu, India, under the guidance of Dr. Inshad Ali Khan, Sr. Principal Scientist, from October 2007 to January 2014 š§Ŗ. He previously completed his M.Sc. in Biotechnology at Guru Nanak Dev University, Amritsar, Punjab, India, from June 2004 to May 2006, after qualifying the CEEB examination conducted by JNU š§¬. Dr. Kalia’s academic journey reflects his dedication to the field of Clinical Microbiology and Biotechnology šš¬. š¬ Research Experience š Dr. Nitin Pal Kalia is an esteemed Assistant Professor at NIPER, Hyderabad, Telangana, India, since February 4, 2021. š Previously, he was honored with the Ramalingaswami Fellowship by the Department of Biotechnology, serving at CSIR-IIIM Jammu from August 16, 2019, to February 1, 2021. š He was a Research Fellow at Lee Kong Chian School of Medicine, NTU Singapore, from October 16, 2015, to August 15, 2019. š Dr. Kalia also gained valuable experience as a Visiting Fellow at NIAID-NIH Bethesda, USA, from May 16, 2014, to July 31, 2015. šš š Trainings Dr. Nitin Pal Kalia has impressive experience in biotech research. From February to July 2007, he worked as a trainee on a project titled āCloning and recombinant expression of Rhabdovirus antigens for vaccine developmentā at Bharat Biotech International Private Limited in Hyderabad under the Biotech Industrial Training Program sponsored by the Department of Biotechnology, Govt. of India š§¬š. Additionally, from June to July 2005, he was a trainee on a project entitled āIdentifying Bacterial Diversity in Natural Environment: a molecular phylogenetic approachā at IHBT-CSIR in Palampur, Himachal Pradesh šæš¬. š Accomplishments Dr. Nitin Pal Kalia has a distinguished record in biosafety and research. š He was awarded the Ramalingaswami Re-entry Fellowship (2017-2018) by DBT, India. His expertise includes BSL-3 training from the National University of Singapore (2016) and NIH USA (2014 & 2015). š§Ŗ He completed hands-on training on laboratory animal care with A*Star Singapore (2015) and holds the IIIM-CSIR award for novel tuberculosis scaffolds (2013). š¦ Dr. Kalia also received the ICMR-Senior Research Fellowship for his work on Staphylococcus aureus (2010) and was sponsored by DBT for industrial training (2007). š§¬ He qualified JNU’s Biotechnology Entrance Exam in 2004. š š¬ Doctoral Research & Post-Doctoral Research Dr. Nitin Pal Kalia focuses on innovative approaches to combat drug-resistant Mycobacterium tuberculosis. His research explores targeting terminal oxidases and cell wall synthesis. Key findings include the use of Q203 to inhibit the respiratory cytochrome bc1 complex and ongoing efforts to identify potent inhibitors for the bd-oxidase. At NIH, he evaluated new chemical entities, profiling them against resistant MTb mutants. During his Ph.D., he discovered capsaicin as an inhibitor of the NorA efflux pump, significantly reducing the invasiveness of Staphylococcus aureus in macrophages. šš¬š¦ š š§ Workshops š Dr. Nitin Pal Kalia has participated in significant workshops, enhancing his expertise in biotechnology and regulatory toxicology. He attended a workshop on āManagement of IPR in Biotechnologyā in Hyderabad, sponsored by the Department of Biotechnology, Government of India (April 26-27, 2007) š±š¬. Additionally, he engaged in an online national workshop on āRole of Regulatory Toxicology and Good Laboratory Practice (GLP) in Drug Discovery and Developmentā conducted by NIPER, Hyderabad (August 27-28, 2020) š»š. These experiences have enriched his knowledge and professional growth in these crucial fields. šāØ š Abstracts presented in conferences Dr. Nitin Pal Kalia has made significant contributions to the field of medicinal chemistry. His research includes a 2022 study, where he explored how capsaicin boosts mupirocin’s efficacy against Staphylococcus aureus by inhibiting the MdeA efflux pump. š§Ŗš¬ In 2013, Dr. Kalia identified novel inhibitors for the multidrug-resistant efflux pump Rv1258c in Mycobacterium tuberculosis. š¦ š His 2010 study highlighted how piperine enhances rifampicin’s protective efficacy against Mycobacterium tuberculosis infection, showcasing its immunomodulatory activity. šæš”ļø His work underscores a commitment to advancing antimicrobial and immunomodulatory therapies. š©āš¬šØāš¬ š Publications Top Notes Capsaicin, a novel inhibitor of the NorA efflux pump, reduces the intracellular invasion ofĀ Staphylococcus aureus Exploiting the synthetic lethality between terminal respiratory oxidases to kill Mycobacterium tuberculosis and clear host infection Piperine analogs as potent Staphylococcus aureus NorA efflux pump inhibitors Sulfur rich 2-mercaptobenzothiazole and 1, 2, 3-triazole conjugates as novel antitubercular agents Piperine as an inhibitor of the MdeA efflux pump ofĀ Staphylococcus aureus Protective efficacy of piperine against Mycobacterium tuberculosis Antimicrobial and Antimycobacterial Activities of Methyl Caffeate Isolated fromĀ Solanum torvumĀ Swartz. Fruit Targeting theĀ Mycobacterium ulceransĀ cytochromeĀ bc1:aa3Ā for the treatment of Buruli ulcer Boeravinone B, A Novel Dual Inhibitor of NorA Bacterial Efflux Pump ofĀ Staphylococcus aureusĀ and HumanĀ P-Glycoprotein, Reduces the Biofilm Formation andĀ ā¦ Dual inhibition of the terminal oxidases eradicates antibioticātolerantĀ Mycobacterium tuberculosis Dr. Nitin Pal Kalia | Immunology and Microbiology | Best Researcher Award